Tags : Iconic Therapeutics

Novartis Signs an Option Agreement with Iconic Therapeutics for its

Shots: Novartis to get an option on Iconic’s ophthalmology program in exchange for an up front payment and equity investment in Iconic Iconic is evaluating its anti-Tissue Factor monoclonal antibody, ICON-4 for the treatment of age-related macular degeneration and plans the onset of clinical studies in 2020 Iconic Therapeutics targets Tissue Factor biology to develop […]Read More

Exelixis Signs an Exclusive Option and License Agreement with Iconic

Shots: Iconic to receive $7.5M upfront, funds for preclinical development and is eligible for option exercise payment, development, regulatory & commercial milestones, royalties on sales. Exelixis to get an option to license Iconic’s ICON-2 ADC program and will exercise its option at IND filing The focus of the collaboration is to robust Exelixis’s oncology portfolio […]Read More